NCT01951846View on ClinicalTrials.gov

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

November 30, 2004

Conditions
Malignant Solid Tumour
Interventions
DRUG

BIBF 1120

Trial Locations (1)

79106

Klinik für Tumorbiologie, Abteilung Internistische Onkologie, Freiburg im Breisgau

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY